论文部分内容阅读
为进一步观察马蔺子素合并放射治疗食管癌的增敏疗效及不良反应，将经病理或细胞学证实的62例食管癌病人，随机分为治疗组（放射治疗加用马蔺子素胶囊）32例和对照（单纯放疗）30例。结果：放疗半量时，治疗组有效率62．5％，对照组10．0％P＜0．05）；放疗全量时，肿瘤全消率治疗组800％，对照组40．0％（P＜0．5）。提示：马蔺子素对食管癌的放疗有显著增敏作用，无明显不良反应。
In order to further observe the sensitizing effect and adverse reactions of irisquinone combined with radiotherapy for esophageal cancer, 62 patients with esophageal cancer confirmed by pathology or cytology were randomly divided into treatment group (radiotherapy plus irisquinone capsule) and control group (Radiotherapy alone) in 30 cases. Results: The effective rate was 62.5% in the treatment group and 10.0% in the control group (P <0.05). When the total amount of radiotherapy was used, the total tumor elimination rate was 800% in the treatment group and 40.0% in the control group (P < 0.5). Tip: irisquinone on esophageal cancer radiotherapy significantly sensitizing effect, no significant adverse reactions.